Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Drug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Fineline Cube Aug 2, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital

Fineline Cube Aug 2, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...

Company Deals

Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China

Fineline Cube Aug 2, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...

Company Drug

Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial

Fineline Cube Aug 2, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies

Fineline Cube Aug 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment

Fineline Cube Aug 2, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China

Fineline Cube Aug 2, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...

Company Drug

Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China

Fineline Cube Aug 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Drug

GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy

Fineline Cube Aug 2, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...

Company Deals

Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia

Fineline Cube Aug 2, 2024

China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...

Company Deals

Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus

Fineline Cube Aug 2, 2024

Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...

Company Deals

Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal

Fineline Cube Aug 2, 2024

Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...

Policy / Regulatory

US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry

Fineline Cube Aug 1, 2024

Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...

Policy / Regulatory

China’s Health Authorities Set Standards for Key Central Township Health Centers

Fineline Cube Aug 1, 2024

The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...

Policy / Regulatory

China’s State Council Unveils Five-Year Plan to Enhance Urbanization and Address “Three Rural Issues”

Fineline Cube Aug 1, 2024

The State Council of China has released a “Five Year Action Plan for Deepening the...

Policy / Regulatory

Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies

Fineline Cube Aug 1, 2024

The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the...

Company Deals Legal / IP

Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations

Fineline Cube Aug 1, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation...

Company Medical Device

MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment

Fineline Cube Aug 1, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company

HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency

Fineline Cube Aug 1, 2024

China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...

Company Drug

Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China

Fineline Cube Aug 1, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...

Posts pagination

1 … 267 268 269 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.